BUCHEN DAVID A 4
4 · Amneal Pharmaceuticals, Inc. · Filed Jan 6, 2020
Insider Transaction Report
Form 4
BUCHEN DAVID A
SVP, Chief Legal Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2020-01-03−27,614→ 82,843 total→ Class A Common Stock (27,614 underlying) - Tax Payment
Class A Common Stock
2020-01-03$4.72/sh−8,188$38,647→ 20,426 total - Exercise/Conversion
Class A Common Stock
2020-01-03+27,614→ 28,614 total
Footnotes (4)
- [F1]Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F3]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
- [F4]On January 3, 2019, the reporting person was granted 110,457 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire.